EcoDrugPlus

Voltage-Dependent Calcium Channel Gamma-1 Subunit-Like

Ensembl ID : ENSMAMG00000023573
Gene Symbol: LOC113141384
2 Cross references
194 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-2 Subunit-Like

Ensembl ID : ENSMAMG00000004906
Gene Symbol: LOC113128420
2 Cross references
200 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-3 Subunit-Like

Ensembl ID : ENSMAMG00000008959
Gene Symbol: LOC113128387
2 Cross references
190 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-4 Subunit-Like

Ensembl ID : ENSMAMG00000024450
Gene Symbol: LOC113141093
3 Cross references
189 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-6 Subunit-Like

Ensembl ID : ENSMAMG00000019250
Gene Symbol: LOC113126866
3 Cross references
182 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-7 Subunit-Like

Ensembl ID : ENSMAMG00000027363
Gene Symbol: LOC113126862
3 Cross references
184 Possible Orthologues:

Voltage-Dependent Calcium Channel Subunit Alpha-2/delta-2-Like

Ensembl ID : ENSMAMG00000023736
Gene Symbol: LOC113130260
2 Cross references
195 Possible Orthologues:

Xanthine Dehydrogenase

Ensembl ID : ENSMAMG00000022670
Gene Symbol: XDH
2 Cross references
208 Possible Orthologues:

Ensembl ID : ENSMAMG00000005393
Gene Symbol: -
Cross references: -
116 Possible Orthologues:

Ensembl ID : ENSMAMG00000020070
Gene Symbol: -
Cross references: -
226 Possible Orthologues:

Ensembl ID : ENSMAMG00000028200
Gene Symbol: -
Cross references: -
184 Possible Orthologues:

Ensembl ID : ENSMAMG00000021006
Gene Symbol: -
Cross references: -
186 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).